Payment overview · 2025
General Payments
$64.26
3 reported records · 2 companies
Healthcare provider profile · identity verified
Becky Ann Thompson, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHOW LOW, AZ · NPI 1740250067
Verified facts
What the public records show
CMS Open Payments records show Becky Ann Thompson, MD received $64.26 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 62.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.09 | 62.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.17 | 37.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $64.26 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 542 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 82 |
| Omeprazole | Omeprazole | 311 | 101 |
| Losartan Potassium | Losartan Potassium | 310 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 90 |
| Lisinopril | Lisinopril | 247 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 74 |
| Montelukast Sodium | Montelukast Sodium | 192 | 54 |
| Gabapentin | Gabapentin | 170 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 63 |
| Trazodone Hcl | Trazodone Hcl | 145 | 43 |
| Metformin Hcl | Metformin Hcl | 140 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 138 | 34 |
| Potassium Chloride | Potassium Chloride | 133 | 47 |
| Furosemide | Furosemide | 127 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 36 |
| Sertraline Hcl | Sertraline Hcl | 117 | 35 |
| Eliquis | Apixaban | 104 | 31 |
| Tramadol Hcl | Tramadol Hcl | 104 | 32 |
| Estradiol | Estradiol | 103 | 38 |
| Prednisone | Prednisone | 103 | 64 |
| Ibandronate Sodium | Ibandronate Sodium | 100 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | 32 |
| Meloxicam | Meloxicam | 92 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 28 |
| Atenolol | Atenolol | 88 | 20 |
| Allopurinol | Allopurinol | 84 | 27 |
| Carvedilol | Carvedilol | 83 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 20 |
| Warfarin Sodium | Warfarin Sodium | 69 | 16 |
| Alprazolam | Alprazolam | 68 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 18 |
| Lorazepam | Lorazepam | 65 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 25 |
| Synthroid | Levothyroxine Sodium | 56 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 15 |
| Buspirone Hcl | Buspirone Hcl | 53 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | 13 |
| Ozempic | Semaglutide | 40 | 14 |
| Simvastatin | Simvastatin | 40 | 12 |
| Celecoxib | Celecoxib | 39 | 13 |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | 12 |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 13 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 14 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 26 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | 12 |
| Temazepam | Temazepam | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Famotidine | Famotidine | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Progesterone | Progesterone, Micronized | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64.26 · 3 records | PFIZER INC. | ABRYSVO, COMIRNATY, JEMPERLI, PREVNAR 20 | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error